Open in interactive viewer → charts, metric popovers & call review

Kyntra Bio’s Last Shot Is an Oral Anemia Drug It Can’t Afford to Test

A CD46 ADC failure forces a pure-play MDS pivot — and the Phase III still hinges on capital that doesn’t exist yet.
KYNB · Earnings Call · 2026-11-16

The pivot nobody wanted

Kyntra Bio’s third-quarter call was not a normal quarterly update; it was a forced reset. The company killed its lead oncology program after an interim efficacy miss: “Unfortunately, based upon insufficient interim efficacy results that did not meet the threshold required to support continued development, we have made the decision to terminate the phase II study of FG-3246 and FG-3180.” — Thane Wettig, Chief Executive Officer · 2026-11-16 The keyword record shows how complete the break is. In the prior quarter, Kyntra’s top themes were CD46 expression, non-PSMA approaches, Pluvicto sequencing and PET imaging. Those concepts did not disappear because the market lost interest; they disappeared because the asset did. The new top keywords are lower-risk MDS, high transfusion burden patients, MATTERHORN study and oral option — the vocabulary of roxadustat, the one program left. The contrast with the prior call is brutal. In May, management still expected FG-3246 to reach mature data:

However, we do expect given the hurdle that we've set, we do expect the asset to continue on until we see the more fully mature rPFS data in 2027.

Thane Wettig, Chief Executive Officer · 2026-05-11
Seven months later, the program is being returned to Fortis and wound down. The tape already voted. KYNB is an $8.3M microcap whose stock is down 70.9% over the last 90 trading days and 73.3% from its July peak; the full-history drawdown is 99.9%. This is not a market-wide wave. Global curated themes this quarter are macro and AI — Fed rate hike, Grok bot, tariff and election noise — none of which explains Kyntra. This is company-unique binary risk.

The asset that remains

Roxadustat is an oral HIF-PHI approved in more than 40 countries for anemia of CKD. Kyntra wants to develop it in lower-risk MDS with high transfusion burden, using post-hoc MATTERHORN data: 36% of roxadustat patients achieved eight-week transfusion independence versus 7% on placebo, and 45% versus 13% over 52 weeks. In ESA-refractory patients the company reported 31% versus 0%. The commercial pitch is an oral option in a population that currently gets injections or infusions, plus an RS-negative segment where luspatercept is not indicated second-line. Management puts peak U.S. sales at about $1B. But the evidence is thin and the safety file is not clean. The high-transfusion-burden subgroup had Grade 3 or higher TEAEs in 65% of roxadustat patients versus 27% on placebo; discontinuations were similar, which management argues shows tolerability. More important, “We did see an imbalance in cardiovascular and thrombotic events in the study... the total number of patients with a significant event were only eight.” — Carrie Brownstein, Vice President, Head of Myeloid Group · 2026-11-16 That is the same issue that helped produce the FDA’s CKD complete response letter. Kyntra says a Type C meeting left the agency “unequivocally” aligned with the 2.5 mg/kg starting dose, and that hematologists can manage thrombosis. Investors will discount that until the Phase III runs.

The funding cliff

The NovaQuest amendment is the one genuinely good financial event. It cut the maximum royalty-backed obligation from $125M to $65M, with only $15M left after a $42.6M accelerated payment; David DeLucia called it “highly accretive” and cited a 26% IRR. Cash was $44.1M at September 30, and “Due to the termination of the FG-3246 and FG-3180 program, we now expect the company to have a cash runway into 2028.” — David DeLucia, Chief Financial Officer · 2026-11-16 That sounds comfortable until you put it next to the trial. On the prior call, management estimated the roxadustat Phase III would cost “in the neighborhood of $50 million to $60 million.” — Thane Wettig, Chief Executive Officer · 2025-11-10 The Q1 2027 start is explicitly conditional: “We are currently on track to initiate this study in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise.” — Thane Wettig, Chief Executive Officer · 2026-11-16 In Q&A, Thane Wettig was blunter: “Really, the rate limiter for us is going to be the funding for the trial.” — Thane Wettig, Chief Executive Officer · 2026-11-16 This is not a new contingency. In August, Matthew Keller asked how contingent the Phase III was on a partner, and Wettig answered: “The start of the phase III, as we've stated previously, we are undergoing both the opportunity to develop internally as well as partner the program.” — Thane Wettig, Chief Executive Officer · 2026-08-13 The difference is that in August there were two programs and a CD46 option; now there is one asset and less negotiating leverage. Michael King pressed exactly that point, asking whether the small post-hoc dataset creates “tension” with potential partners. Wettig conceded the dataset is small but argued “there are parties who look at our MATTERHORN data and are highly interested.” That may be true; it is not financing. The balance sheet remains fragile. Liabilities stood at 108% of assets at the July quarter-end, and the operating loss was still negative $18M. The $44M cash balance buys time, not a trial.

What would change the story

A signed partnership or a credible external raise would turn this from a broken oncology story into a funded rare-disease option. Without one, the “pure-play” label is premature: Q1 2027 slips, the MATTERHORN post-hoc remains a small subgroup, and the equity becomes a call option on a financing market that has already watched the stock fall 70% in 90 days. The market is not debating the size of the MDS opportunity; it is debating whether Kyntra can pay to prove it.